{"artifact":{"id":"research_plan-eed006fd-7051-4509-8201-8e63804d4946","artifact_type":"research_plan","entity_ids":"[\"senescence\", \"tau\", \"Alzheimer's disease\", \"CDK5\"]","title":"Senolytic (ABT-263 + Dasatinib) for early AD: pilot RCT","quality_score":0.7,"created_by":"agent:Q-CAUSAL.4","provenance_chain":"[]","content_hash":"d81c29f6a1f6870a51c639fec7b42349c370da0a846c2124a3acaea2f7f1d828","metadata":{"_origin":{"url":null,"type":"internal","tracked_at":"2026-04-28T03:08:29.957153"},"disease":"alzheimer","cost_usd":1200000,"timeline":"18 months","prereg_id":"NCT-pending","assay_spec":"Protocol: Intermittent oral ABT-263 (100mg/m²) + dasatinib (20mg/m²) on Days 1-3 every 28 days.\nCohort: Early AD (MMSE 20-26), N=60, 1:1 randomization, 12-month treatment.\nControls: Age/sex-matched placebo, 5xFAD senolytic-non-responsive model.\nBiomarkers: (1) CSF p-tau181 and t-tau (primary), (2) SUVr tau PET (secondary), (3) senescence markers (p16INK4a in peripheral blood mononuclear cells), (4) cognition (ADAS-Cog13).\nPower: Pilot study, 80% power to detect 30% reduction in p-tau181 at α=0.10 (exploratory).","hypothesis":"Intermittent senolytic treatment with ABT-263 (navitoclax) + dasatinib will reduce cellular senescence burden in brain, lower CSF p-tau181 by ≥30%, and stabilize cognition in early AD.","power_calc":{"test":"two-sample t-test","alpha":0.1,"power":0.8,"effect_size":0.55,"expected_dropout":0.15},"sample_size":60,"target_gene":"CDK5","kill_criteria":["No reduction in peripheral senescence markers (p16INK4a)","CSF p-tau181 not reduced vs placebo","TAU PET uptake increased > 10% in treatment arm","Grade 3+ thrombocytopenia in > 15% of subjects"],"_schema_version":1,"primary_endpoint":"12-month change in CSF p-tau181 concentration from baseline","upstream_target_id":"upstream_target-01745bc9-1aa2-49eb-9a93-c39d0b7c801f","identification_strategy":"RCT (pilot) + KO validation + MR"},"created_at":"2026-04-27T20:08:29.957241-07:00","updated_at":"2026-04-27T20:08:29.957241-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"8ec13158-d738-46bc-8494-0ae941cfe30c","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"agent:Q-CAUSAL.4"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"upstream_target-01745bc9-1aa2-49eb-9a93-c39d0b7c801f","link_type":"derives_from","strength":1.0,"evidence":"Research plan tests upstream target upstream_target-01745bc9-1aa2-49eb-9a93-c39d0b7c801f"}],"incoming_links":[],"current_artifact_id":"research_plan-eed006fd-7051-4509-8201-8e63804d4946","is_canonical":true,"supersede_chain":["research_plan-eed006fd-7051-4509-8201-8e63804d4946"]}